Kornimate/medical-research-clean huggingface dataset:
incidence of cystitis in women consuming a mixture of cranberry, cinnamon, probiotics

Conditions: Cystitis; Urinary Tract Infections

Summary: cranberries are traditionally used for urinary comfort and prevention of urinary disorders of bacterial origin and despite an efsa opinion invalidating the clinical efficacy of cranberries, its mechanism of action has been several times proposed by the scientific community: it would act by inhibiting the synthesis of p-fimbriae leading to a complete disappearance of these adhesins, and to bacterial-type deformation by lengthening of the cell body. cinnamon and microbiotic strains could enhance this synergy. this study aims to evaluate the effectiveness of a food supplement based on cranberry, cinnamon and microbiotic strains (feminabiane cbu) on the symptoms of cystitis, urinary discomfort and the number of cystitis reported by women.

women who use or not the cranberry, cinnamon, and microbiotic blend are encouraged to complete a 6-month diary in which they report any urinary tract disorders they encounter.

Eligibility criteria:
inclusion criteria: * having at least 2 symptomatic episodes of cystitis during the last 6 months including at least 1 episode confirmed as being bacterial cystitis (by an urine bacterial analysis or validated by a doctor (date of appointment, list of prescribed treatments) ; * whose symptomatic episodes of cystitis over the past 6 months have had a significant impact on quality of life / urinary comfort (acss qol\> 2); * having a smartphone compatible with the nurstrial® data collection application; * not opposing the collection and processing of their personal data. exclusion criteria: * presenting urinary discomfort with a severe impact on quality of life (acss qol\> 7) during the last 24 hours prior to inclusion; * pregnant, breastfeeding or planning to become pregnant during the study; * under antibiotic treatment (or during the last month preceding inclusion); * under food supplementation with prebiotics or probiotics or having stopped it less than a month before inclusion; * having had recourse to a prophylactic treatment (cranberry juice) 15 days before inclusion; * having had local estrogen therapy during the 3 months preceding inclusion; * diabetic; * presenting an immunosuppressive disease; * presenting pelvic floor abnormalities (cystocele surgery, etc.); * presenting or having a history of kidney disease (including kidney stones, urinary tract abnormalities, pyelonephritis, kidney failure, kidney transplantation); * for women consuming supplementation: known allergy to plants of the cranberry family or to one of the components of the products.
treatment of primary breast cancer using pdt

Conditions: Breast Neoplasms

Summary: phase i/iia, open label, non-randomised, single site trial in patients with primary breast cancer.

this is a phase i / iia study recruiting patients diagnosed with primary breast cancer. patients who have chosen mastectomy or wide local excision as their surgical option will be included. patients will have a pre therapy mri followed by photodynamic therapy. pdt involves intravenously injecting the photosensitizer verteporfin (visudyne) drug. this drug makes the tumour sensitive to light. a non-thermal light will then be shone in the tumour which brings about tissue necrosis (destruction). although the drug dose will remain the same, the light dose will be escalated depending on patient response in accordance to a predefined algorithm (see section) to achieve a zone of necrosis of 12mm or a plateau of necrosis with incremental increase in light dose. an mri will be performed immediately prior to the scheduled surgery. pre and post pdt mri changes will be correlated with the histological findings on the excised breast specimen. should the minimum light dose for 12mm necrosis be established recruitment will continue until 12 patients have received this dose. these 12 patients will provide sample data on the size of tumour and area of necrosis detected by mri and histology to enable sample size (power) calculations for future studies of pdt in primary breast cancer. this is a dose escalation study involving a minimum of twelve and a maximum of forty patients.

Eligibility criteria:
inclusion criteria: 1. patients aged 30 or over 2. a uni-focal invasive ductal breast carcinoma or discrete uni-focal site which is deemed suitable for pdt within a multifocal invasive ductal carcinoma in a single breast. 3. patients who have opted for mastectomy or wide local excision as primary treatment. 4. capable of giving written informed consent exclusion criteria: 1. patients who are not undergoing surgery as their primary treatment. 2. patients undergoing surgery for dcis without invasive breast cancer. 3. patients with lobular cancer 4. patients with necrotic tumours 5. distant metastatic disease. 6. patients will be excluded if they have porphyria or are sensitive to verteporfin (visudyne). 7. patients who have severe cardiovascular disease. 8. patients with severe or uncontrolled systemic disease e.g. hepatic impairment. 9. patients with laboratory findings that make it undesirable for the patient to participate in the trial. 10. male breast cancer patients 11. pregnancy and lactation. 12. no patients with any psychiatric disorder making reliable informed consent impossible. 13. patients will be excluded if taking part in any other trial of an experimental medicine 14. patients will be excluded if taking endocrine therapy drugs that could confound the results.

Keywords: early breast cancer photodynamic therapy pdt visudyne verteporfin
anti-gravity treadmill training in patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the aim of this study is to compare anti-gravity treadmill training with traditional treadmill training in patients with moderate to severe knee osteoarthritis.

patients with moderate to severe oa have persistent pain that significantly affects their functional status, activity participation, and quality of life. as with mild oa, non-pharmacological interventions that focus on education, exercise, and weight management are first-line treatments for patients with moderate to severe knee oa. exercise is recommended for all patients with moderate to severe knee oa to reduce pain and protect the joint. a meta-analysis showed that exercise has beneficial effects on pain, even in patients with severe disease and awaiting total knee replacement.therefore, the objective of this study was to compare the effects of anti-gravity treadmill training and traditional treadmill training on pain levels, quality of life and functional capacity in patients with moderate and severe knee osteoarthritis. in addition, it was aimed to compare the compliance of the patients to aerobic exercise.

Eligibility criteria:
inclusion criteria: * female patients ≥ 50 and ≤ 75 years old * patients with a diagnosis of knee oa in at least one knee according to the classification criteria of the american college of rheumatology * patients with kellgren-lawrence (k-l) knee oa staging iii to iv * patients reporting knee pain on most days of the past month * patients with stable medical and psychological status * patients willing to participate in the study exclusion criteria: patients with serious cardiovascular, pulmonary, neurological disease or other musculoskeletal problems (inflammatory rheumatic disease, active synovitis, severe low back pain, hip/knee joint replacement or other hip/knee-related trauma, fracture, or surgery) that impair walking * patients with a history of corticosteroid injection to the knee in the last 3 months * patients who have received opioid analgesics or systemic corticosteroids in the last 3 months * patients who have undergone any exercise program or physical therapy program for the lower extremities in the last 3 months * patients with severe vision, hearing and language problems * patients with a body mass index ≥35 kg /m²
a study to evaluate the dose response and safety of pha-794428 in adults with growth hormone deficiency

Conditions: Growth Hormone Deficiency

Summary: the purpose of this study is to explore the safety, toleration and dose response of pha-794428 after multiple weekly injections in male and female growth hormone deficient patients.

the study terminated on 10-dec-2007. pfizer's decision to terminate the program was due to cases of injection-site lipoatrophy that were reported in the clinical phase 2 studies after a single injection of pha 794428.

Eligibility criteria:
inclusion criteria: * male and female patients with severe aghd. * hypopituitary patients must be on adequate hormone replacement therapy for at least 6 months. exclusion criteria: * aghd patients with uncontrolled pituitary tumor growth. * tumors within 3 mm of the optic chiasm. * patients with diabetes mellitus.
titanium-sapphire laser trabeculoplasty in glaucoma: a randomized study comparing titanium-sapphire with argon laser trabeculoplasty in open-angle glaucoma patients

Conditions: Glaucoma, Open-Angle

Summary: titanium sapphire laser trabeculoplasty is effective in lowering intraocular pressure in glaucoma patients, and is comparable to argon laser trabeculoplasty

objective: to compare the medium-term outcome of titanium-sapphire laser trabeculoplasty (tislt) vs. argon laser trabeculoplasty (alt) in uncontrolled open-angle glaucoma (oag) patients. methods: prospective, masked, randomized comparative clinical study. thirty-seven oag patients with uncontrolled iop and no previous filtration surgery (22 females and 15 males, mean age of 68 years) participated. eighteen were treated with tislt and 19 with alt. all patients underwent a comprehensive eye examination including visual acuity, iop, goniocscopy and slit-lamp biomicroscopy and visual field examinations. patients were examined pre-operatively and then at 1 hour, 1 day, 1 week, 1, 3 and 6 months, 1 year and 18 months post-operatively. main outcome measures: final iop, delta iop and number of anti-glaucoma medications. results: the 18 patients in the tislt arm had an average of 8.3(±2.7) mm hg or 32% reduction from pre-operative iop (p\ 0.05). tislt patients had statistically significant fewer iop spikes compared to the alt group. (p=0.002). two patients (1 in each arm) underwent trabeculectomy and were considered failures. mean follow-up time was 15 months. conclusions: tislt provides similar efficacy to alt in iop reduction in oag patients, and may offer better safety with fewer iop spikes see post-operatively. application to clinical practice: if confirmed in additional studies, tislt may be used as an alternative to alt in oag patients.

Eligibility criteria:
inclusion criteria: * uncontrolled open angle glaucoma patients

Keywords: laser trabeculoplasty, glaucoma, argon, titanium-sapphire iop lowering effect adverse effects iop spikes
a comparison of lma-supreme and i-gel for the incidence of postoperative sore throat

Conditions: General Anesthesia

Summary: the purpose of this study is to investigate and compare the incidence of the postoperative sore throat between lma supreme and i-gel.


Eligibility criteria:
inclusion criteria: - adult patients aged over 19 years who are scheduled for elective surgery under general anesthesia using the laryngeal mask airway exclusion criteria: * anticipated difficult airway * expected duration of surgery more than 4 hours * body mass index more than 35 kg/m2 * pregnancy * upper gastrointestinal surgery or open abdominal surgery.
post prandial individual responses to different foods

Conditions: PreDiabetes; Diabetes Mellitus, Type 2; Healthy

Summary: this study aims to understand why people respond differently to the same foods, especially when it comes to changes in blood sugar after eating. a continuous glucose monitors (cgms) will be used to observe how individuals respond to specific meals and drinks (e.g., oral glucose tolerance test, ogtt). by studying these patterns, the investigators hope to identify different types of metabolism and see if certain foods or food ingredients (like fiber, amino acids, or vinegar) can help control blood sugar better for specific groups. this research will help lay the groundwork for personalized dietary advice based on a person's unique biology.

participants in the study will be provided with a continuous glucose monitor (cgm) and pre-measured cooked rice to test with different potential mitigators: fiber, acid, amino acid (e.g., leucine), whole protein, and exercise. each of these conditions will be tested on a different day following strict instructions. for some of these tests, participants will be asked to collect a blood microsample and a saliva sample before and after eating the test meal. a stool sample will be collected at baseline.

Eligibility criteria:
inclusion criteria: * bmi (body mass index) \>19 kg/m2 but \< 45 kg/m2 * hba1c \< or equal to 7.0% while not on antihyperglycemic medications * be willing to provide written informed consent for all study procedures. * able to commute to stanford campus for on-site visits exclusion criteria: * recent (\<6mos) cvd (cardiovascular disease) event * active malignancy * kidney/liver disease * pregnancy/lactation * chronic inflammatory disease * eating disorder * bariatric surgery * history of acute pancreatitis * current use of antihyperglycemic, diabetogenic, or weight loss medications * heavy alcohol use * physical activity \>2 hours/day * inability to come to stanford ctru (clinical and translational research unit) for metabolic testing
4d fdg pet in esophageal cancer

Conditions: Esophageal Cancer

Summary: fdg pet-ct image acquisition in the abdominal and thoracic region is influenced by organ motion. respiratory movement blurs the metabolic signal of the esophageal tumor and lymph nodes. the investigators hypothesize that the metabolic signal obtained with motion compensation results in higher suv-max values and clearer demarcation of the esophageal tumor and lymph nodes.

patients will receive a normal 3d fdg pet-ct scan. by participating in this trial, one extra 4d ct scan will be made. for both the pet and the 4d ct acquisition, the patient gets an abdominal belt around the waist to register breathing motion. no extra fdg pet scan is required for this study. the 4d ct scan is the only intervention which increases the radiation dose exposure compared to the standard pet-ct scan. however, in comparison to the expected radiation dose delivered, if a patient will be treated with curative chemoradiotherapy, this increase in radiation dose is negligible and secondary risks due to this intervention are therefore not increased. for patients who are not eligible for curative treatment the extra dose is also not relevant, given the life expectancy of this group.

Eligibility criteria:
inclusion criteria: * patients with pathology proven esophageal cancer or tumor highly suspicious for esophageal cancer * \> 18 years * written informed consent exclusion criteria: * \<18 years * possibility of pregnancy

Keywords: 4d pet-ct
the effect of non invasive electrical stimulation therapy on gastroesophageal reflux disease (gerd) symptoms - proof of concept study

Conditions: Gastroesophageal Reflux Disease

Summary: the aims of the study: to evaluate whether the use of a specific tens technology can improve gerd symptoms and esophageal acid exposure.


Eligibility criteria:
inclusion criteria: * at least 3 episodes of heartburn and/or regurgitation in a week for at least 3 months. * evidence for an abnormal esophagal acid exposure on impedance-ph monitoring (tested in the last 2 years off ppi) exclusion criteria: * gastric or esophagal surgery * active peptic ulcer disease * malignancy * pregnancy * uncontrolled diabetes mellitus * severe cardiac conditions such as cardiac arrhythmia or ischemia or cardiac pacemaker/defibrillator * allergy to adhesives/patches * severe pulmonary disease * obesity (bmi\>30)
pathologic assessment of rectal prolapse in the young

Conditions: Rectal Prolapse

Summary: patients aging less than 45 years with rectal prolapse will undergo full pathologic and functional assessment to determine the underlying etiology.

full clinical assessment of the patients will be conducted by history taking querying the type and duration of symptoms, associated medical conditions, history of previous surgery for rectal prolapse, and presence of fecal incontinence which will be graded by wexner continence score. in addition, patients will undergo thorough general and local examination to determine the type of rectal prolapse (internal or external) and the condition of the anal sphincters and pelvic floor muscles. functional assessment of the anorectal region will be done by anal manometry to measure the resting and squeeze anal pressures, rectal sensation and compliance; endorectal ultrasonography to assess the integrity of the anal sphincters; and pudendal nerve terminal motor latency (pntml) to exclude pudendal neuropathy. random biopsies (2-4 in number) will be taken from the pelvic floor muscles, external anal sphincter, and the lateral supportive ligaments of the rectum during surgical treatment of rectal prolapse whether via the abdominal or perineal approach. tissue samples will be preserved in formalin solution and will be sent for histopathological examination. tissue samples will be subjected to immunohistochemistry to calculate the ratio between collagen type i and type iii, and to reveal any myopathic or degenerative changes. additionally, schistosomal affection of the pelvic floor muscles will be detected by immunohistochemistry examination for the ova of schistosomal mansoni.

Eligibility criteria:
inclusion criteria: * patients of both genders aging below 45 years with primary or recurrent rectal prolapse, whether internal or external prolapse exclusion criteria: * patients above 45 years, patients with associated anorectal pathology as anal fissure, hemorrhoids or neoplasm, and patients with documented psychiatric or mental disorders.
anatomical resection in colorectal liver metastases patients

Conditions: The Characteristics of CRLM Patients Who Would Benefit More From Anatomical Resection

Summary: the type of liver resection (anatomical resection, ar or nonanatomical resection, nar) for colorectal liver metastases (crlm) is subject to debate. the debate may persist because some certain prognostic factors, associated with aggressive biological behavior of tumor, have been overlooked. the aim of our study was to investigate the characteristics of patients who would benefit more from anatomical resection for colorectal liver metastases.

729 patients who underwent hepatic resection of crlm were retrospectively collected from june 2012and may 2019. treatment effects between ar and nar were compared in full subgroup analyses. tumor relapse-free survival (rfs) was evaluated by a stratified log-rank test and summarized with the use of kaplan-meier and cox proportional hazards methods.

Eligibility criteria:
inclusion criteria: (1)age 18-79 years;(2) histologically proven colorectal adenocarcinoma; exclusion criteria: (1) the histologic type of tumor was not called adenocarcinoma; (2) peritoneal metastasis; (3) number of liver metastasis \>3; (4) simultaneous anatomical and nonanatomical resections; (5) r2 resection; (6) history of previous hepatectomy; (7) incomplete data. the rest of patients were divided into 2 groups: patients undergoing an ar, and patients undergoing a nar.
comprehensive treatment for different types of tumor thrombi in the portal vein for hepatocellular carcinoma patients

Conditions: Hepatocellular Carcinoma; Portal Vein Tumor Thrombus

Summary: this study is working to evaluate the surgical comprehensive treatment for different types of tumor thrombi in the portal vein for hepatocellular carcinoma patients, to establish a standardized, unified, effective therapeutic program.

primary liver cancer (plc) has a great tendency to invade portal vein intravascularly, results in the formation of portal vein tumor thrombus (pvtt), which is a crucial factor that can worsen the prognosis of patients with plc. in clinical, various treatments have been applied to improve this short-term prognosis, but there was no identical indication for treatment of plc patients with different pvtt. the objective of this study is to evaluate the surgical comprehensive treatment for different types of tumor thrombi in the portal vein for hepatocellular carcinoma patients, to establish a standardized, unified, effective therapeutic program.

Eligibility criteria:
inclusion criteria: * male or female patients \> 30 years and \<=60 years of age. * with a clinical diagnosis of primary liver cancer with pvtt, without any adjuvant therapy. * resectable tumors in the liver. * pvtt type for ii or iii (based on the pvtt type system established by our groups), confirmed through pre-operative imaging and pathologic examination. * liver function grade a or b of the child-pugh classification. * no dysfunction in major organs; blood routine, kidney function, cardiac function and lung function are basically normal. hb ≥95g/l,wbc ≥3.000 cells/mm³,platelets ≥80.000 cells/mm³. * patients who can understand this trial and have signed information consent. exclusion criteria: * have had an allergic reaction following iodine or chemotherapeutic drugs. * with extrahepatic metastasis. * patients with apparent cardiac, pulmonary, cerebral and renal dysfunction,which may affect the treatment of liver cancer. * liver function:child c.

Keywords: hepatocellular carcinoma portal vein tumor thrombus surgical comprehensive treatment
optimization of human cortical stimulation

Conditions: Epilepsy; Brain Injury

Summary: we will observe epileptic patients who already have electrodes implanted on the brain and are receiving high-level brain stimulation for clinical purposes while testing their motor and language function. we propose to do a limited, low-level brain stimulation to show that the signatures of local activity in the target area change as an effect of brain stimulation. the goal of this study is to understand the feasibility of a novel recurrent brain-computer interface that could eventually promote targeted functional recovery in subjects who have had a brain injury.

the subject will have already been scheduled for placement of the ecog electrodes on the surface of the brain and who will, for all clinical purposes, subsequently receive stimulation for mapping of function of the ecog sites. the decision to place the electrodes on the brain, the location of the electrodes and the length of time the electrodes are in are all part of clinical care. there will be two types of testing, motor and language. motor will involve inducing stimulation to the thumb cortex and the wrist cortex. there will be a conditioning of this over 4-12 hours. language will involve showing pictures on a computer screen and the subject will be observed whether speech is disrupted with stimulation or not.

Eligibility criteria:
inclusion criteria: * age 18 and older * male and female * able to understand english for consenting and testing * referred for surgical implantation of electrodes exclusion criteria: * under 18 years of age * pregnant women * prisoners * mentally disabled iq \< 70 * non english speaking * not candidates for surgical implantation of electrodes

Keywords: ecog epilepsy cortical stimulation electrocorticography electrodes mapping